Response

We are heartened by the interest of Drs Zhu and Xu1 in our work.2 Regarding bridging, the medical decision making behind bridging off warfarin comes from active comanagement by our region-wide anticoagulation service. Their current guidelines are aligned with the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway, which recommends the consideration of bridging for patients with a moderate to high thrombotic risk (CHA2DS2-VASc of 5 to 6, or 7+).3 In our methods, we stated that we excluded patients who were receiving single-agent therapy with heparin, clopidogrel, and low-molecular-weight heparin.
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research